tiprankstipranks
OpGen Inc (OPGN)
OTHER OTC:OPGN

OpGen (OPGN) AI Stock Analysis

Compare
597 Followers

Top Page

OP

OpGen

(OTC:OPGN)

40Underperform
OpGen's overall stock score is low due to significant financial challenges, including declining revenues, negative profitability, and reliance on external financing. Technical indicators suggest a bearish trend with potential overbought conditions, and valuation metrics highlight unprofitability. These factors collectively indicate substantial risk and uncertainty in the company's near-term performance.

OpGen (OPGN) vs. S&P 500 (SPY)

OpGen Business Overview & Revenue Model

Company DescriptionOpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It helps to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
How the Company Makes MoneyOpGen generates revenue primarily through the sale of its diagnostic products and services. The company's revenue model is based on selling its molecular diagnostic tests, such as the Acuitas AMR Gene Panel and the Unyvero platform, to hospitals, laboratories, and healthcare providers. Additionally, OpGen earns income from service agreements, where it provides testing services using its proprietary technology. Key partnerships with healthcare institutions and collaborations with other biotech firms enhance its market reach and contribute to its earnings. The company's focus on addressing challenges related to antimicrobial resistance creates a demand for its products, further driving its revenue streams.

OpGen Financial Statement Overview

Summary
OpGen is struggling financially with declining revenues, consistent losses, and cash flow challenges. While there are some signs of improvement in equity, high leverage and dependency on external financing raise concerns about financial sustainability and risk management. Efforts to improve operational efficiency and cost management are crucial for future stability.
Income Statement
30
Negative
OpGen experienced a significant decline in revenue from 2023 to 2024 TTM, with a negative gross profit margin indicating cost challenges. The net profit margin is also negative due to consistent losses, reflecting ongoing unprofitability. EBIT and EBITDA margins are similarly negative, highlighting operational inefficiencies and high expenses relative to revenue.
Balance Sheet
45
Neutral
The balance sheet shows improvement in stockholders' equity moving from negative to positive in 2024 TTM, improving its financial stability. However, the company still faces high leverage with a significant amount of total debt relative to equity, posing risks of financial instability.
Cash Flow
35
Negative
Cash flow remains a concern with negative operating and free cash flow, indicating cash outflows that surpass cash inflows from operations. Although there is substantial financing inflow, reliance on external funding increases financial risk and sustainability concerns.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
1.27M3.42M2.61M4.31M4.21M3.50M
Gross Profit
54.79K-90.69K-816.70K1.46M365.95K1.87M
EBIT
-20.99M-15.69M-34.57M-23.10M-21.49M-10.97M
EBITDA
-10.91M-29.51M-32.38M-20.39M-19.16M-10.05M
Net Income Common Stockholders
-9.30M-32.67M-36.74M-34.81M-26.21M-11.71M
Balance SheetCash, Cash Equivalents and Short-Term Investments
4.57M1.15M7.44M36.08M13.36M2.71M
Total Assets
8.95M1.88M25.83M71.67M49.75M10.42M
Total Debt
1.90M13.04M14.84M25.18M22.85M3.16M
Net Debt
-2.68M11.89M7.40M-10.90M9.49M451.76K
Total Liabilities
5.64M13.44M18.25M30.45M28.56M6.13M
Stockholders Equity
3.31M-11.56M7.58M41.22M21.19M4.29M
Cash FlowFree Cash Flow
-6.31M-15.12M-21.04M-23.46M-23.53M-11.54M
Operating Cash Flow
-6.31M-14.32M-20.45M-21.48M-23.40M-11.51M
Investing Cash Flow
-914.00-800.41K-590.77K-1.98M-1.06M-2.50M
Financing Cash Flow
7.22M8.37M-6.74M47.45M34.09M12.17M

OpGen Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.68
Price Trends
50DMA
1.06
Positive
100DMA
1.26
Positive
200DMA
1.83
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
65.14
Neutral
STOCH
66.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPGN, the sentiment is Positive. The current price of 1.68 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.06, and below the 200-day MA of 1.83, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 65.14 is Neutral, neither overbought nor oversold. The STOCH value of 66.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OPGN.

OpGen Risk Analysis

OpGen disclosed 20 risk factors in its most recent earnings report. OpGen reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

OpGen Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$1.02B18.6019.46%19.07%
52
Neutral
$260.30M25.27-4.64%-54.17%-135.78%
49
Neutral
$6.84B0.05-53.14%2.48%24.49%-3.26%
46
Neutral
$2.52B-50.74%-7.03%-20233.78%
40
Underperform
$6.93M-331.94%-58.77%80.26%
35
Underperform
$3.70M366.81%-30.19%97.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OPGN
OpGen
1.68
-3.27
-66.06%
OSUR
Orasure Technologies
3.41
-3.47
-50.44%
QDEL
QuidelOrtho
35.60
-11.88
-25.02%
CDNA
CareDx
17.64
7.67
76.93%
TTOO
T2 Biosystems
0.12
-3.90
-97.01%

OpGen Corporate Events

Executive/Board Changes
OpGen Appoints New COO and Company Secretary
Neutral
Dec 6, 2024

OpGen, Inc. appoints Mohd Azham Azudin as COO and Gillian Tan Rou Yee as Company Secretary, bringing extensive experience in private equity and corporate law, respectively. Azudin, with over 25 years in investment roles, will earn a base salary of $50,000, potentially convertible to equity. Tan, a seasoned legal professional, will receive $25,000, also convertible to equity, highlighting OpGen’s strategic focus on experienced leadership and flexible compensation structures.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.